---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000593"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2024-01-26T23:59:59+00:00"
generated_at: "2026-06-06T16:27:02.998163+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MaxCyte announces departure of Chief Scientific Officer Cenk Sumen

## Summary
- Cenk Sumen, Ph.D., ended employment as Chief Scientific Officer on January 23, 2024.
- He will receive 9 months of base salary and COBRA continuation under his severance agreement.
- Sumen will remain on MaxCyte's Scientific Advisory Board.
- Severance benefits are contingent on execution of a release of claims agreement.

## SEC filing metadata
- accession: 0001558370-24-000593
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2024-01-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837024000593/0001558370-24-000593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837024000593/mxct-20240123x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000593
- JSON: https://secwatch.observer/filing/0001558370-24-000593.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000593.txt

## Key facts
- Executive change
  Cenk Sumen departed as Chief Scientific Officer at MAXCYTE, INC..
  - Action: ended
  - Role: Chief Scientific Officer
  source text: On January 23, 2024, Cenk Sumen, Ph.D.’s employment as Chief Scientific Officer of MaxCyte, Inc. (the “ Company ”), ended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837024000593/0001558370-24-000593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.